<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tyra Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/tyra-biosciences-inc</link>
<description>Latest news and press releases for Tyra Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tyra-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835cf5a78dffbe2df11ed22.webp</url>
<title>Tyra Biosciences Inc</title>
<link>https://6ix.com/company/tyra-biosciences-inc</link>
</image>
<item>
<title>Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-appointment-of-habib-dable-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-appointment-of-habib-dable-to-its-board-of-directors</guid>
<pubDate>Fri, 17 Apr 2026 12:00:00 GMT</pubDate>
<description>Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.</description>
</item>
<item>
<title>Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-highlights</guid>
<pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
<description>Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and highlighted recent corporate progress.</description>
</item>
<item>
<title>Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-poster-presentations-at-the-2026-ascor-genitourinary-gu-cancers-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-poster-presentations-at-the-2026-ascor-genitourinary-gu-cancers-symposium</guid>
<pubDate>Mon, 23 Feb 2026 22:30:00 GMT</pubDate>
<description>Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being held February 26-28, 2026, in San Francisco, California.</description>
</item>
<item>
<title>Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-strengthens-leadership-team-appointments-bhavesh-ashar-chief</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-strengthens-leadership-team-appointments-bhavesh-ashar-chief</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Tyra Biosciences Announces Participation at Upcoming Investor Events</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-participation-upcoming-investor-events-2025-11-12</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-participation-upcoming-investor-events-2025-11-12</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-third-quarter-2025-financial-results-and-highlights-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-third-quarter-2025-financial-results-and-highlights-2025-11</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 - - Expanded development of dabogratinib</description>
</item>
<item>
<title>Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-first-child-dosed-beach301-its-phase-2-study-dabogratinib</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-first-child-dosed-beach301-its-phase-2-study-dabogratinib</guid>
<pubDate>Thu, 21 Aug 2025 04:00:00 GMT</pubDate>
<description>-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in</description>
</item>
<item>
<title>Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-second-quarter-2025-financial-results-and-highlights-2025-08</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-second-quarter-2025-financial-results-and-highlights-2025-08</guid>
<pubDate>Thu, 14 Aug 2025 04:00:00 GMT</pubDate>
<description>- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of</description>
</item>
<item>
<title>Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-fireside-chat-achondroplasia-and-growth-disorders-ubs</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-fireside-chat-achondroplasia-and-growth-disorders-ubs</guid>
<pubDate>Mon, 21 Jul 2025 04:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-late-breaking-poster-presentation-tyra-300-preclinical</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-late-breaking-poster-presentation-tyra-300-preclinical</guid>
<pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., July 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-doses-first-patient-phase-2-study-tyra-300-low-grade-intermediate</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-doses-first-patient-phase-2-study-tyra-300-low-grade-intermediate</guid>
<pubDate>Mon, 30 Jun 2025 04:00:00 GMT</pubDate>
<description>-TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data expected to</description>
</item>
<item>
<title>Tyra Biosciences to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-participate-upcoming-investor-conferences-2025-05-12</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-participate-upcoming-investor-conferences-2025-05-12</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., May 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-first-quarter-2025-financial-results-and-highlights-2025-05</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-first-quarter-2025-financial-results-and-highlights-2025-05</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>- BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment - - Initiated patient dosing in SURF431 study of TYRA-430 for</description>
</item>
<item>
<title>Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and</guid>
<pubDate>Thu, 27 Mar 2025 04:00:00 GMT</pubDate>
<description>- Three INDs cleared by US FDA for TYRA's proprietary precision small molecules - - TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for</description>
</item>
<item>
<title>Tyra Biosciences to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-present-upcoming-investor-conferences-2025-02-11</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-present-upcoming-investor-conferences-2025-02-11</guid>
<pubDate>Tue, 11 Feb 2025 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Feb. 11, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-appointment-adele-gulfo-board-directors-2025-01-29</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-appointment-adele-gulfo-board-directors-2025-01-29</guid>
<pubDate>Wed, 29 Jan 2025 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-poster-presentations-2025-asco-gastrointestinal-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-announces-poster-presentations-2025-asco-gastrointestinal-cancers</guid>
<pubDate>Wed, 22 Jan 2025 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Jan. 22, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing</description>
</item>
<item>
<title>Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-receives-ind-clearance-fda-proceed-phase-2-study-tyra-300-non-muscle</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-receives-ind-clearance-fda-proceed-phase-2-study-tyra-300-non-muscle</guid>
<pubDate>Fri, 10 Jan 2025 05:00:00 GMT</pubDate>
<description>-TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2</description>
</item>
<item>
<title>Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights-2024-11</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights-2024-11</guid>
<pubDate>Thu, 07 Nov 2024 05:00:00 GMT</pubDate>
<description>- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in</description>
</item>
<item>
<title>Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)</title>
<link>https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-receives-ind-clearance-fda-proceed-phase-2-study-tyra-300-pediatric</link>
<guid isPermaLink="true">https://6ix.com/company/tyra-biosciences-inc/news/tyra-biosciences-receives-ind-clearance-fda-proceed-phase-2-study-tyra-300-pediatric</guid>
<pubDate>Mon, 28 Oct 2024 04:00:00 GMT</pubDate>
<description>– TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies – – First child with achondroplasia expected to be dosed in</description>
</item>
</channel>
</rss>